Related Experiment Video
Updated: Feb 10, 2026

Ischemia-reperfusion Model of Acute Kidney Injury and Post Injury Fibrosis in Mice
Published on: August 9, 2013
Acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam administration: a systematic
Xiao-Yu Chen1, Ri-Xiang Xu1, Xin Zhou1
1Department of Pharmacology, School of Pharmacy, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, People's Republic of China.
Background:
As a tricyclic glycopeptide antibiotic used to treat acute infections, Vancomycin (VAN) is often administered with piperacillin/tazobactam (PT) to treat various infections in clinical practice. However, whether the combination of these two drugs, compared to VAN alone, can cause an increased risk of acute kidney injury (AKI) remains controversial.
Objectives:
This study aims to identify the correlation between the development of AKI and the combined use of VAN and PT.
Methods:
We conducted a meta-analysis of eight observational cohort studies (a total of 10727 participants received VAN and PT versus VAN and other β-lactams). PubMed, Chinese Biological Medicine Database (CBM), China National Knowledge Infrastructure (CNKI) Database, Wan Fang Digital Periodicals Database (WFDP), and China Science Citation Database (CSCD) were searched through April 2017 using "vancomycin" and "piperacillin" and "tazobactam" as well as "acute kidney injury" or "acute renal failure" or "AKI" or "ARF" or "nephrotoxicity." Two reviewers extracted the data and assessed the risk of bias.
Results:
A correlation was found between the development of AKI and concurrent use of VAN and PT compared with concomitant VAN and β-lactams (OR 1.57; 95% CI, 1.13-2.01; I2 = 76.4%, p < 0.001). Similar findings were obtained in an analysis of studies comparing concurrent VAN and PT use with concurrent VAN and β-lactam (cefepime) use (OR 1.50; 95% CI, 1.07-1.93; I2 = 80.5%, p < 0.001). Exclusion of fair-quality and low-quality articles did not change the results (OR 1.49; 95% CI, 1.06-1.92; I2 = 84.1%, p < 0.001).
Conclusions:
Regarding β-lactam therapy in clinical practice, an elevated risk of AKI due to the combined use of VAN and PT should be considered.
Insights
The combination of vancomycin (VAN) and piperacillin/tazobactam (PT) is associated with a higher risk of acute kidney injury (AKI). This finding suggests careful consideration of VAN and PT use in clinical practice to mitigate potential kidney damage.
Area of Science:
- Pharmacology
- Nephrology
- Infectious Diseases
Background:
- Vancomycin (VAN) is a critical antibiotic for acute infections, often co-administered with piperacillin/tazobactam (PT).
- The potential for this combination to increase the risk of acute kidney injury (AKI) compared to VAN alone is a subject of ongoing clinical debate.
Purpose of the Study:
- To investigate the correlation between the concurrent administration of VAN and PT and the incidence of AKI.
- To provide evidence-based insights into the nephrotoxic potential of this common drug combination.
Main Methods:
- A meta-analysis was performed on eight observational cohort studies, encompassing 10,727 participants.
- Comprehensive literature searches were conducted across major databases (PubMed, CBM, CNKI, WFDP, CSCD) up to April 2017.
- Data extraction and risk of bias assessment were performed by two independent reviewers.
Main Results:
- A statistically significant correlation was identified between the combined use of VAN and PT and an increased risk of AKI (OR 1.57; 95% CI, 1.13-2.01).
- This association remained consistent even when comparing VAN and PT to VAN and cefepime (OR 1.50; 95% CI, 1.07-1.93).
- Sensitivity analyses excluding lower-quality studies did not alter the observed correlation (OR 1.49; 95% CI, 1.06-1.92).
Conclusions:
- The concurrent use of vancomycin and piperacillin/tazobactam is associated with an elevated risk of acute kidney injury.
- Clinicians should carefully consider this increased nephrotoxicity risk when prescribing VAN and PT in combination.
- Further research may be warranted to explore mechanisms and mitigation strategies for VAN-PT-induced AKI.
Related Concept Videos
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention

